Safety profiles of dasatinib in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
Japanese Journal of Clinical Oncology · 2026
DOI: 10.1093/jjco/hyaf154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2026. Verfasst von Yuanyuan Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy of the Second Affiliated Hospital, Shantou University Medical College, No. 69 Dongxia North Road, Jinping District, Shantou 51…. Hauptthemen laut MEDLINE: Dasatinib, Pharmacovigilance, Adverse Drug Reaction Reporting Systems, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: 'Construction and application of an anticancer drug knowledge graph based on a science popularization public account', ‘Construction and application of an anticancer drug knowledge graph based on a science popularization public account’.
Abstract (Originalsprache)
Objective
Dasatinib was approved for treating pediatric patients with philadelphia chromosome-positive chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. While its efficacy has been proven, comprehensive safety data in pediatric populations remain limited. This study utilizes data from the food and drug administration adverse event reporting system (FAERS) to evaluate and characterize adverse events (AEs) reported in pediatric patients treated with dasatinib.
Methods
Data from the FAERS between 2014 Q1 and 2024 Q4 were analyzed. Disproportionality analysis was performed to identify AEs reported in pediatric patients treated with dasatinib.
Results
A total of 382 pediatric cases involving dasatinib were reported. The most frequent system organ classes included general disorders and administration site conditions, injury, poisoning, and procedural complications, and gastrointestinal disorders. Notably, previously unreported AEs such as hemorrhagic enterocolitis, lymphoid tissue hyperplasia, hydrocephalus, and hemorrhagic cystitis were identified, raising potential new safety concerns. Additionally, instances of off-label use were observed, particularly in regions where dasatinib is not recommended for pediatric patients, underscoring the importance of vigilant AEs monitoring to ensure patient safety.
Conclusion
This study highlights the need for enhanced pharmacovigilance and proactive monitoring in pediatric patients receiving dasatinib to ensure treatment safety and improve clinical outcomes, and provides supporting evidence for the safe use of dasatinib in pediatric populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy of the Second Affiliated Hospital, Shantou University Medical College, No. 69 Dongxia North Road, Jinping District, Shantou 515041, Guangdong, China.
ORCID-Profile: Yuanyuan Yang, Yan Lin
Förderung
- 'Construction and application of an anticancer drug knowledge graph based on a science popularization public account'
- ‘Construction and application of an anticancer drug knowledge graph based on a science popularization public account’
Zitieren
APA
Yang, Y., Ma, W., Fu, H., Zhou, Y., & Lin, Y. (2026). Safety profiles of dasatinib in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf154
Vancouver
Yang Y, Ma W, Fu H, Zhou Y, Lin Y. Safety profiles of dasatinib in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database. Japanese Journal of Clinical Oncology. 2026. doi:10.1093/jjco/hyaf154
BibTeX
@article{Yang2026,
author = {Yang, Yuanyuan and Ma, Weihao and Fu, Hongbo and Zhou, Yanqiong and Lin, Yan},
title = {Safety profiles of dasatinib in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database},
journal = {Japanese Journal of Clinical Oncology},
year = {2026},
doi = {10.1093/jjco/hyaf154}
}
EUVIMED